Closely held Pipeline Therapeutics named Evert (Eef) Schimmelpennink to its board. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development...
Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...
Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...
Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...
Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...
180 Life Sciences (NASDAQ:ATNF) formed a scientific advisory board (SAB) whose initial composition will include Prof. Raphael Mechoulam of Hebrew University, Israel; Dr. Kevin Tracey, of Hofstra/Northwell; Prof. Irene...
Revive Therapeutics (OTCQB:RVVTF; CSE:RVV; FRANKFURT:31R) received orphan drug designation from the FDA for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. ...
Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Eddie Cheung, M.D., FACG, to lead the company’s strategic medical affairs in Asia, a newly-created position. Dr. Cheung will explore and identify possible...
Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International. Shares...
Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment in Part B of the Phase 2 TRAVERS clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The company expects to release top-line...
Brookline Capital Markets initiated coverage of Caribou Biosciences (NASDAQ:CRBU) with a “buy” rating and 12-to-18-month price target of $19. The stock closed at $10.71 on Feb. 11. Caribou is a leading next...
BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...